Bladder cancer (BCa) exhibits favorable responses to immunotherapy, but a significant percentage of patients fail to show a response owing to an inadequate tumor-immune landscape.
We previously showed that NK cells are one of the predominant tumor-infiltrating lymphocytes in BCa and correlate with improved patient survival.
However, that link was observed only with CD56
